Avalo Therapeutics Stock Cash And Equivalents
| AVTX Stock | USD 9.55 0.44 4.40% |
Avalo Therapeutics fundamentals help investors to digest information that contributes to Avalo Therapeutics' financial success or failures. It also enables traders to predict the movement of Avalo Stock. The fundamental analysis module provides a way to measure Avalo Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Avalo Therapeutics stock.
Avalo | Cash And Equivalents |
Avalo Therapeutics Company Cash And Equivalents Analysis
Avalo Therapeutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Avalo Therapeutics Cash And Equivalents | 11.25 M |
Most of Avalo Therapeutics' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Avalo Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Avalo Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for Avalo Therapeutics is extremely important. It helps to project a fair market value of Avalo Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Avalo Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Avalo Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Avalo Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Avalo Therapeutics has 11.25 M in Cash And Equivalents. This is 98.63% lower than that of the Biotechnology sector and 97.48% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 99.58% higher than that of the company.
Avalo Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Avalo Therapeutics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Avalo Therapeutics could also be used in its relative valuation, which is a method of valuing Avalo Therapeutics by comparing valuation metrics of similar companies.Avalo Therapeutics is currently under evaluation in cash and equivalents category among its peers.
Avalo Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Avalo Therapeutics from analyzing Avalo Therapeutics' financial statements. These drivers represent accounts that assess Avalo Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Avalo Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 112.3M | 308.1M | 194.0M | 47.4M | 2.5M | 2.4M | |
| Enterprise Value | 117.0M | 305.8M | 175.5M | 53.7M | (4.4M) | (4.1M) |
Avalo Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Avalo Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Avalo Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Avalo Fundamentals
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.31 | ||||
| Operating Margin | (51.65) % | ||||
| Current Valuation | 23.22 M | ||||
| Shares Outstanding | 10.46 M | ||||
| Shares Owned By Insiders | 5.86 % | ||||
| Shares Owned By Institutions | 64.99 % | ||||
| Number Of Shares Shorted | 10.06 K | ||||
| Price To Book | 4.96 X | ||||
| Price To Sales | 127.48 X | ||||
| Revenue | 1.92 M | ||||
| Gross Profit | (7.94 M) | ||||
| EBITDA | (27.95 M) | ||||
| Net Income | (31.54 M) | ||||
| Cash And Equivalents | 11.25 M | ||||
| Cash Per Share | 1.20 X | ||||
| Total Debt | 537 K | ||||
| Debt To Equity | 5.62 % | ||||
| Current Ratio | 0.98 X | ||||
| Book Value Per Share | 2.18 X | ||||
| Cash Flow From Operations | (30.68 M) | ||||
| Short Ratio | 0.18 X | ||||
| Earnings Per Share | 94.42 X | ||||
| Target Price | 35.0 | ||||
| Number Of Employees | 19 | ||||
| Beta | 1.03 | ||||
| Market Capitalization | 104.53 M | ||||
| Total Asset | 20.99 M | ||||
| Retained Earnings | (335.13 M) | ||||
| Working Capital | 3.78 M | ||||
| Net Asset | 20.99 M |
About Avalo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Avalo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avalo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avalo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Avalo Stock Analysis
When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.